2261-P: Clinical and Demographic Profiles of Individuals with Diabetes and End-Stage Kidney Disease on Dialysis: A U.S. Nationwide Analysis from 2013 to 2017

Introduction and Objective: Diabetes mellitus (DM) is a common cause of end-stage kidney disease (ESKD). Few studies have compared characteristics of patients with type 1 (T1D) and type 2 diabetes (T2D) undergoing dialysis, particularly with respect to hypoglycemia. Methods: We conducted a retrospective analysis of United States Renal Data System (USRDS) data (2013-2017) including adults (≥18 years) with DM on dialysis for ≥3 months. Descriptive statistics were used, and crude and adjusted severe hypoglycemia (requiring hospitalization or ED visits) rates per 1,000 person-years were calculated across demographic, clinical, and treatment subgroups (p 0.05 was considered significant). Results: Among 273,569 individuals included, up to 29,290 (10.7%) have T1D and 244,279 (89.3%) had T2D. Patient characteristics are summarized in Table 1. Those with T1D were younger and had fewer cardiovascular and pulmonary comorbidities. Severe hypoglycemia was consistently more frequent in T1D than T2D across comparable insulin regimens: 101.73 vs 83.22 for human basal/human bolus regimens; 113.22 vs 79.29 for human basal/analog bolus; 168.29 vs 100.41 for analog basal/human bolus; and 172.08 vs 97.04 for analog basal/analog bolus regimens. Conclusion: Compared with T2D, patients with T1D on dialysis are younger, have fewer comorbidities, and experience higher rates of severe hypoglycemia regardless of the type of insulin. Disclosure J. Martins de Oliveira: None. D. Soliman: None. A.J. Macias: None. F. Vendrame: None. S. Inselman: None. R. McCoy: None. G. Umpierrez: Research Support; Current; Abbott, Dexcom, Inc., Bayer AG. Advisory Panel; Ended; Sanofi-Aventis U.S., Dexcom, Inc. Other - Education grant; Current; Lilly Diabetes, Abbott Diabetes. Advisory Panel; Current; Glycare, Glucotrack. Research Support; Current; Corcept Therapeutics. R.J. Galindo: Consultant; Ended; Abbott, Boehringer Ingelheim International GmbH, Dexcom, Inc., Eli Lilly and Company, Gan Current; Roche Pharmaceuticals, Boehringer Ingelheim International GmbH, Novo Nordisk.